Article 23 provides that interested parties must have the legal means to prevent the use of a geographical indication from which wines originate for wines of origin not indicated in the geographical indication. This also applies when the public is not misled, there is no unfair competition, the true origin of the goods is indicated, or the geographical indication is accompanied by expressions such as nature, type, style, counterfeiting or other. Similar protection should be given to geographical indications identifying spirit drinks when used in spirit drinks. Protection against trademark registration must be provided accordingly. An agreement reached in 2003 relaxed domestic market requirements and allows developing countries to export to other countries with a public health problem as long as exported drugs are not part of a trade or industrial policy.  Drugs exported under such regulations may be packaged or coloured differently to prevent them from affecting the markets of industrialized countries. With the TRIPS agreement, intellectual property rights have been integrated into the multilateral trading system for the first time and remains the most comprehensive multilateral IP agreement to date. In 2001, developing countries, fearing that developed countries had insisted on too narrow a reading of the TRIPS trip, launched a series of discussions that culminated in the Doha Declaration. The Doha Declaration is a WTO DECLARATION that clarifies the scope of the TRIPS agreement, which states, for example, that TRIPS can and should be interpreted in light of the objective of “promoting access to medicines for all”. The TRIPS agreement contains, in reference to the provisions of the Berne Convention on the Protection of Literary and Artistic Works (Art.
9), with the exception of moral rights. It has also incorporated, referring to the material provisions of the Paris Convention on the Protection of Industrial Property (Article 2.1). The TRIPS agreement explicitly states that software and databases are copyrighted and subject to the originality requirement (Article 10). Among these agreements, the ip rights trade (TRIPS) aspects are expected to have the greatest impact on the pharmaceutical sector and access to medicines. The TRIPS agreement has been in force since 1995 and is the most comprehensive multilateral IP agreement to date. The TRIPS agreement introduced global minimum standards for the protection and enforcement of almost all forms of intellectual property rights (IPRs), including patent rights. International agreements prior to TRIPS did not contain minimum patent standards. At the time negotiations began, more than 40 countries around the world did not grant patent protection for pharmaceuticals. The TRIPS agreement now requires all WTO members, with a few exceptions, to adapt their legislation to minimum standards of intellectual property protection. In addition, the TRIPS agreement introduced detailed obligations to respect intellectual property rights. Article 40 of the TRIPS ON Agreement recognizes that certain practices or licensing conditions related to intellectual property rights that limit competition can have negative effects on trade and impede the transfer and dissemination of technology (paragraph 1).